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 What is Known: 
 There are limited studies comparing bare metal stents (BMS) to drug eluting stents 
(DES) for percutaneous coronary intervention (PCI) for saphenous vein grafts (SVG). 
 In general, these studies suggest that DES are associated with reduced repeat 
revascularization but no survival benefit.   
 These studies are mainly of 1st generation DES and there are now 2nd generation 
stents and more recent studies suggest that newer generation stents have lower 
mortality than BMS but no differences in mortality between newer and 1st generation 
DES. 
What the Study Adds: 
 We observe that patients receiving DES for the treatment of SVG disease have lower 
rates of in-hospital MACE, 30-day mortality and 1-year mortality, compared with 
those receiving BMS.   
 The reduction in adverse outcomes is greatest with newer generation DES.   
 Patients undergoing PCI for SVG disease should be considered for treatment with 
DES, unless there are any contraindications such as higher risk of bleeding with 
DAPT or requirement for a short DAPT course. 
Abstract 
Background: There are limited data on comparison of contemporary drug eluting stent 
platforms (DES), previous generation DES and bare metal stents (BMS) for percutaneous 
coronary intervention (PCI) in saphenous vein grafts (SVG). We aimed to assess clinical 
outcomes following PCI to SVG in patients receiving bare metal stents (BMS), 1
st
 generation 
DES and newer generation DES in a large unselected national dataset from the British 
Cardiovascular Intervention Society (BCIS). 
Methods and Results: Patients undergoing PCI to SVG in the UK from January 2006 to 
December 2013 were divided into three groups according to stent use: BMS, 1
st
 generation 
DES and newer generation DES group. Study outcomes included in-hospital major adverse 
cardiovascular events (MACE), 30-day and 1-year mortality. 15,003 patients underwent PCI 
to SVG in England and Wales during the study period. Of these 38% received BMS, 15% 
received 1
st
 generation DES and 47% received 2
nd
 generation DES. The rates of in-hospital 
MACE were significantly lower in patients treated with 2
nd
 generation DES (OR 0.51, 95% 
CI 0.38-0.68, P<0.001), but not with 1
st
 generation DES, compared with BMS treated 
patients. Similarly, 30-day mortality (OR 0.43, 95% CI 0.32-0.59, p<0.001) and 1-year 
mortality (OR 0.60, 95% CI 0.51-0.71, p<0.001) were lower in patients treated with 2
nd
 
generation DES, but not with 1
st
 generation DES, compared to the patients treated with BMS. 
Conclusion: Patients receiving 2
nd
 generation DES for the treatment SVG disease have lower 
rates of in-hospital MACE, 30-day mortality and 1-year mortality, compared with those 
receiving BMS. 
Keywords: Coronary artery bypass graft, saphenous vein graft, percutaneous coronary 
intervention, mortality, cardiovascular events 
  
 Coronary artery bypass graft surgery (CABG) with one or more saphenous vein grafts 
(SVGs) is a commonly selected mode of revascularization for patients with multi-vessel 
coronary artery disease.  The long-term patency rates of SVGs, when compared to arterial 
conduits, remain poor despite optimal secondary prevention therapy.
1
 A sizeable proportion 
(10-40%) of SVGs occlude within the first year and with inexorable attrition at a rate of 2-5% 
annually, which accelerates with graft age.
2-10
 Although patients can undergo redo CABG, 
there is high morbidity and mortality associated with this. Therefore, percutaneous coronary 
intervention (PCI) of SVGs is often a preferred revascularization modality in patients with 
significant SVG disease
11,12
 with 5-10% of all PCI procedures being undertaken in SVGs.
11,13
 
For treating native coronary arteries, drug eluting stents (DES) are preferred over the 
bare metal stents (BMS) as DES have been shown to reduce repeat revascularization and 
major adverse cardiac events (MACE).
14
 However, there are situations where a BMS can be 
more appropriate, for example when a short duration of dual antiplatelet therapy is desirable 
or for treating focal lesions in large diameter vessels.
14,15
 As old degenerative SVGs are 
usually of a large calibre and these patients are frequently old and frail with multiple 
comorbidities, BMS may be considered an appropriate choice. Indeed, different registries 
have shown that from one-third to half of patients undergoing PCI of SVGs receive BMS. 
However, more recent data suggest a growing use of newer generation DES in treating SVG 
disease.
16
 
Only a few studies have compared BMS and DES for PCI of SVGs and generally 
shown that use of DES in SVGs can reduce the need for repeat revascularization but with no 
survival benefit.
17-22
 However, these studies have largely compared either only 1
st
 generation 
DES or a combination of 1
st
 and newer generation DES against BMS with limited data on 
contemporary DES platforms. Conversely, data from the DELAYED RRISC trial reported 
worse outcomes for patients with 1
st
 generation sirolimus-eluting stents compared to BMS 
(29% vs 0%, p<0.001 for mortality, 58% vs 41%, p=0.13 for MACE during 3 year follow 
up).
20
 In contrast, more contemporary registry data from the Veterans Affairs CART Program 
suggests use of newer generation DES is associated with lower mortality than BMS (HR 
0.72, 95% CI 0.57-0.89) and similar rates of MI (HR 0.94, 95% CI 0.71-1.24) at long term 
follow up (>2 years), but there was no difference in mortality or MI between 1
st
 and newer 
generation DES in this study.
16
 In view of limited and divergent results in the literature, we 
aimed to assess stent choice and clinical outcomes following PCI to SVGs in patients 
receiving BMS, 1
st
 generation DES and newer generation DES in a large unselected all-
comer national dataset from the British Cardiovascular Intervention Society (BCIS). 
 
Methods 
Study design and data collection 
The BCIS database records information on PCI procedures in UK with data collection 
managed by the National Institute of Cardiovascular Outcomes Research (NICOR).
23-27
 This 
is a retrospective analysis of prospectively collected national data for all patients undergoing 
PCI of SVGs in the UK from January 2006 to December 2013. Using the Medical Research 
Information Services, we tracked participants in this database via the patient's NHS number, a 
unique identifier for any person registered within the NHS in England and Wales, for 
mortality and adverse outcomes.  Institutional review board approval and patient consent was 
not obtained because this study was an analysis routinely collected anonymized data. 
Variables and outcomes collected 
We collected data on participants’ demographics (age, gender, smoking status, family 
history of heart disease) and comorbidities (diabetes, hypertension, hyperlipidemia, previous 
myocardial infarction (MI), stroke, peripheral vascular disease, and renal disease). In 
addition, data were also collected on left ventricular ejection fraction (LVEF), access site, use 
of glycoprotein IIb/IIIa inhibitor, use of thrombectomy device, cardiogenic shock, use of 
intra-aortic balloon pump, use of ventilatory support and use of distal protection devices. 
Patients undergoing PCI to an SVG were grouped into three cohorts based on stent 
type i.e. BMS group (including Titan-2®), 1
st
 generation DES (Cypher®, Taxus Liberte®, 
Eucatax®, Achieve®, Sorin®, Costar® stents) and newer generation DES (Promus®, 
Xience®, Resolute®, Biomatrix®, Endeavor®, Biofreedom®, Nobori® and Yukon® stents). 
We evaluated all-cause mortality at 30-days and 1-year follow up and major adverse 
cardiovascular events (MACE, defined as a composite of in-hospital mortality, in-hospital 
myocardial re-infarction and target vessel revascularization). 
Statistical methods 
We excluded patients with missing data for 30-day mortality, stent type or age. A 
flow diagram graphically describes how the final cohort was derived (Figure 1).  Summary 
statistics are presented as mean ± standard deviation for continuous data and percentage or 
proportions for categorical variables, according to stent group (BMS, 1
st
 generation DES and 
2
nd
 generation DES). The clinical characteristics of the three groups were compared using 
ANOVA or Chi-square tests for continuous and categorical variables respectively.  The risk 
of adverse outcomes was estimated with multiple logistic regressions with imputation for 
missing variables. Multiple imputations by chained equations was performed using mi impute 
chained function in Stata to generate 10 complete datasets. We also calculated the propensity 
score for each stent group and used it to match and estimate adjusted risk estimates in 
pairwise stent group comparisons (BMS vs 1
st
 generation DES, BMS vs 2
nd
 generation DES 
and 1
st
 generation vs 2
nd
 generation DES). To achieve this we used the teffects psmatch 
function in Stata to estimate the average treatment effects while accounting for baseline 
differences across the groups.  For each group member, we calculated propensity scores using 
all the covariates across the 10 imputed datasets.  Using the standard setting for matching, a 
minimum of one neighbour was matched for all observations.  Tolerance for the overlap 
assumption was set to 10
-5
. For consistency with the main analyses and an easier comparison, 
we transformed the differences in probability to odds ratios, after making assumptions about 
the baseline probability risk with BMS. Statistical analyses were performed using Stata v13 
(Stata Corp., Texas, USA). 
Results 
Study cohort 
A total of 18,985 patients underwent PCI to at least one SVG in England and Wales 
from January 2006 to December 2013.  The study cohort with complete data for stent type 
and 30-day mortality was 15,003 (79.0%) as 3,982 patients had missing values for type of 
stent used (3671 patients) or 30-day mortality (311 patients) (Figure 1). The characteristics of 
those included in the study and those excluded are shown in Supplementary Table 1. A total 
of 5,685 (38%) patients received BMS and 9,318 (62%) received DES. Among patients 
receiving DES, 2,265 (24.3%) received 1
st
 generation DES and 7,053 (75.7%) received 2
nd
 
generation DES. There was a temporal change in the use of stents (Figure 2). In 2007, 42% of 
patients received BMS with the remainder receiving 1
st
 generation DES.  By 2013 use 1
st
 
generation DES had ceased with the ratio of newer generation DES to BMS being 78% to 
22% respectively. 
Characteristics of participants 
The characteristics of patients in the three groups are shown in Table 1. There were 
significant differences in the demographic and clinical characteristics within groups, in 
particular, patients treated with 1
st
 generation DES being younger. Comorbidities such as 
diabetes, hypertension, hyperlipidemia, previous MI, and peripheral vascular disease were 
more prevalent in patients receiving 2
nd
 generation DES.  Multi-vessel disease was 
significantly different among stent types (21% vs 27% vs 14%) for 2
nd
 generation DES, 1
st
 
generation DES and BMS, respectively. 
Clinical outcomes  
The highest un-adjusted rates of in-hospital MACE and 30-day and 1-year mortality 
were observed in the BMS group. We found that the in-hospital MACE rate according to 
stent type was 3% (n=167), 1% (n=31) and 2% (103) for BMS, 1st generation DES and 2nd 
generation DES, respectively.  Mortality rates were also significantly lower for DES 
compared to BMS at both 30 days (3% (n=171), 0.9% (n=21) and 1% (n=94)) and 365 days 
(9% (n=491) vs 5% (n=106) vs 6% (n=371)).  The specific components of MACE according 
to stent type is shown in Supplementary Table 2.  Adjusted MACE and mortality were also 
significantly lower with the use of DES (Table 2). For in-hospital MACE, 2
nd
 generation stent 
use was associated with a significant reduction in odds of MACE (OR 0.51, 95% CI 0.38-
0.68, p<0.001) compared to BMS. The risk for adjusted 30-day mortality was significantly 
lower in patients with 2
nd
 generation DES (OR 0.43, 95% CI 0.32-0.59, p<0.001) with a trend 
towards lower risk that was not significant for 1
st
 generation DES (OR 0.63, 95% CI 0.37-
1.10; p=0.104) compared to BMS. At longer follow up of 1 year, only 2
nd
 generation stents 
were associated with decreased mortality (OR 0.60 95% CI 0.51-0.71, p<0.001) compared to 
BMS. 
Propensity score matching for adverse outcomes 
The results of propensity score matching are shown in Table 3 and the matching 
success diagnostics is shown in Supplementary Table 3. For in-hospital MACE, use of both 
1
st
 and 2
nd
 generation DES significantly reduced events compared with BMS (Table 3). 
Similarly, use of 1
st
 or 2
nd
 generation DES was associated with significant reductions in 30-
day mortality (p<0.001 and p<0.001) when compared with BMS. For 1-year mortality, there 
was a reduction with use of 2
nd
 generation DES (p<0.001) but not with 1
st
 generation DES 
(p=0.373), compared with BMS.  The effects were generally small, but statistically 
significant because the outcomes are rare (see Table 1). For example, 1
st
 generation DES was 
estimated 1.29% less likely to be associated with in-hospital MACE than BMS, but the 
baseline probability risk for BMS is 3%. The results after transforming probabilities to odds 
ratios are reported in Supplementary Table 4. In the propensity score matching analyses, we 
continued observing the positive associations for both 1
st
 and 2
nd
 generation DES with 
outcomes, compared to BMS. 
 
Discussion 
Our data, derived from a large all-comer national registry of patients undergoing PCI 
of SVG, suggest that use of DES is associated with better outcomes compared with BMS. 
There is reduction is MACE and mortality in DES treated patients, in particular those 
receiving newer generation DES. 
Our study overcomes the limitations of small sample size seen in the three 
randomized trial (RRISC, SOS, and ISAR-CABG) comparing DES and BMS in SVG lesions. 
RRISC (Reduction of Restenosis In Saphenous vein grafts with Cypher stent) was a 
prospective, double blind, randomized trial of patients (n=75 patients, 96 SVG lesions) 
treated with 1
st
 generation sirolimus-eluting Cypher (Cordis Ltd., New Jersey, USA) DES 
(n=38 patients, 60 stents) or BMS (n=37 patients, 54 stents). The two groups were well 
balanced for baseline clinical and angiographic characteristics. At six months follow-up, the 
DES group had less in-stent restenosis (DES 11.3% vs BMS 30.6%; RR 0.37; 95% CI 0.15-
0.97, p=0.024), target lesion revascularization (DES 5.3% vs BMS21.6%; RR 0.24, 95% CI 
0.05-1.0, p=0.047) and target vessel revascularization (DES 5.3% vs BMS 27%; RR 0.19; 
95% CI 0.05-0.83, p=0.012). Median neo-intimal volume on intravascular ultrasound (IVUS) 
was also substantially reduced in DES group (DES 1 mm
3
 vs BMS 24 mm
3
, p<0.001). Death 
and MI rates were not different at 6-months.
19
 A post-hoc, long-term follow-up, DELAYED 
RRISC (Death and Events at Long-term follow-up AnalYsis: extended duration of Reduction 
of Restenosis In Saphenous vein grafts with Cypher stent) was subsequently conducted to 
report clinical events up to three years (median 32 months) after the index procedure. An 
increase in death rate in DES patients (DES 29% vs BMS 0% p<0.001) was observed, though 
the trial was not powered for clinical outcomes. There were eleven all-cause and seven 
cardiac deaths in the DES group. Stent thrombosis according to ARC criteria occurred in five 
DES patients.
20
 However, patients receiving DES were mandated to receive dual anti-platelet 
therapy for only 2 months, which could potentially explain higher rates of stent thrombosis 
and mortality in the DES group. The SOS (Stenting of Saphenous Vein Grafts) trial 
randomized 80 patients with 112 lesions in 88 SVGs to a BMS (39 patients, 43 grafts, 55 
lesions) or 1
st
 generation paclitaxel-eluting Taxus® (Boston Scientific Corp., Minnesota, 
USA) DES (41 patients, 45 grafts, 57 lesions). Binary angiographic restenosis was 
substantially lower in DES group (DES 9% vs BMS 51%; RR 0.18, 95% CI 0.07-0.48, 
P<0.001). During a median follow-up of 1.5 years the DES group had less target lesion 
revascularization (28% vs. 5%; HR 0.38; 95% CI 0.15-0.74, p=0.003) and target vessel 
failure (46% vs. 22%; HR 0.65, 95% CI 0.42-0.96, p=0.03), a trend toward less target vessel 
revascularization (31% vs. 15%; HR 0.66, 95% CI 0.39-1.05, p=0.08) and MI (31% vs. 15%; 
HR 0.67, 95% CI 0.40-1.08, p=0.10).
21
 However, there was no difference in mortality (5% 
vs. 12%; HR 1.56, 95% CI 0.72-4.11, p=0.27) at 1.5 years.
21
 Extended clinical follow-up 
(median of 35 months) was subsequently obtained showing no difference in all-cause (HR 
2.04, p=0.19) or cardiac mortality (HR 0.62, p=0.51).
22
 However, the DES group had a lower 
incidence of MI (HR 0.32, p=0.01), target lesion revascularization (HR 0.20, p=0.004), target 
vessel revascularization (HR 0.41, p=0.03), and target vessel failure (HR 0.34, p=0.001) as 
well as a trend toward less definite or probable stent thrombosis (HR: 0.15, p=0.08).
22
 The 
larger ISAR-CABG trial (n=610) randomized patients with diseased SVGs to DES (one of 
three types: permanent-polymer paclitaxel-eluting stents, permanent-polymer sirolimus-
eluting stents, or biodegradable-polymer sirolimus-eluting stents) and BMS and reported a 
reduction in the primary endpoint of MACE at 1-year in the DES group (DES 15.4% vs. 
BMS 22.1%, p=0.03) which was mainly driven by a near 50% relative reduction in the risk of 
target lesion revascularization (DES 7.2% vs. BMS 13.1%, p=0.02), with no significant 
differences in mortality.
18
 A meta-analysis comparing DES with BMS in SVG intervention 
(which also included nonrandomized studies) has reported lower mortality, MACE, target 
lesion revascularization, and target vessel revascularization without increased risk of MI or 
stent thrombosis.
28
 Multiple other meta-analyses comparing DES with BMS in SVG 
intervention have demonstrated consistent results of improved efficacy with DES and no 
significant safety hazards.
29-35
  
Our data provide supportive evidence that use of newer generation DES is associated 
with improved outcomes and survival in patients undergoing PCI in SVGs. These findings 
are consistent with another contemporary registry of PCI in SVGs.
16
 It is possible that the 
difference in outcomes are due to the fact that BMS are being used in older or high-risk 
patients or in patients with other morbidities that are not collected in registry datasets. 
Nevertheless, propensity-matching analysis from the Veterans Affairs CART Program,
16
  
data from older patients in the Medicare-linked NCDR CathPCI Registry
36
 and our 
propensity-matched analysis suggest that the advantage seen with DES use may not be all due 
to differences in conventionally-measured patient characteristics. It is therefore possible that 
this survival advantage with 2
nd
 generation DES is a real entity. DES use reduces restenosis, 
need for repeat revascularization and associated adverse events. However, it is also plausible 
that this is not the only mechanism for improved outcomes. The newer generation DES with 
biocompatible and bioresorbable polymers have very low rate for stent thrombosis, which is 
definitely lower than 1
st
 generation DES and possibly also lower than BMS. Moreover, DES 
use is generally associated with longer duration of dual anti-platelet therapy, which may in 
turn be associated with a reduction in adverse ischemic and thrombotic events.
37
 The 
association with a survival advantage seen with newer generation DES in the treatment of 
SVGs is also consistent with recently reported meta-analysis of 51 clinical trials (n=52,158 
patients) showing that newer generation DES are associated with lower rates of mortality, 
stent thrombosis, and MI than BMS and 1
st 
generation DES for the treatment of native 
coronary arteries.
38
 An adequately powered randomized controlled trial is warranted to 
confirm these findings. 
There are no randomized data comparing newer vs. 1
st
 generation DES for the 
treatment of SVG disease. In a multicenter analysis of 172 real-world patients comparing 
first-generation DES, SVG intervention with sirolimus- and paclitaxel-eluting stents resulted 
in non-significant differences in survival (HR: 1.28, 95% CI: 0.39 to 4.25, p = 0.69) and 
target vessel revascularization (HR: 2.54, 95% CI: 0.84 to 7.72, p = 0.09).
39
 Previously, there 
have been very limited data on use of newer generation DES for PCI to SVGs. In the SOS-
Xience V (Stenting of Saphenous Grafts with Xience V) study, 40 patients with SVG lesions 
were treated with a newer generation everolimus-eluting stent (Xience-V, Abbott Vascular 
Ltd., Santa Clara, USA). Out of these 40 patients, 27 underwent 12-month coronary 
angiography and 12 (only 1 of whom had in-stent restenosis) also had follow-up OCT 
evaluation. OCT strut-level analysis (n=2584 struts) showed that 96% struts were covered at 
12-months; however, 9% struts were mal-apposed.
40
 These findings can potentially create 
uncertainty about the role of newer generation DES in treating SVG lesions. Our data from a 
large all-comer national registry and propensity-matched cohort provide further reassurance 
that the newer generation DES appear effective and safe for the treatment of SVG disease. 
 Finally, whilst BMS have conventionally been used in older, multi-morbid patients at 
higher risk of bleeding complications where shorter DAPT duration would be preferable, the 
recent LEADERS FREE trial using a polymer and carrier-free biolimus coated BioFreedom 
stent (Biosensors Europe) was superior to a bare-metal stent with respect to the primary 
safety and efficacy end points when used with a 1-month course of dual antiplatelet therapy
41
 
in patients at high risk of bleeding complications. It is therefore likely that the use of BMS in 
SVG will decline further. 
Study strengths and limitations 
The strengths of these data are that it represents amongst the largest analysis of PCI to 
SVG in contemporary practice, including an almost complete collection of all PCI procedures 
performed in England and Wales. It therefore reflects an all-comers, real-world experience 
that includes many high-risk patients who are often excluded from randomized controlled 
trials. 
This study has several potential limitations. First, whilst mortality tracking within the 
UK is very robust, the cause of death is not currently available, and the MACE outcomes are 
self-reported and are not formally adjudicated. Therefore, the analysis is subject to reporting 
biases, and complications may be under-reported. Secondly, we do not have data for duration 
of DAPT. Thirdly, our analysis report outcomes derived from grafts as the BCIS dataset does 
not differentiate between venous and arterial grafts. Previous data derived from the National 
Cardiovascular Data Registry (NCDR) CathPCI registry suggests that arterial grafts 
represented 2.5% of all PCI procedures undertaken to bypass grafts in the United States 
hence it is likely that the majority of graft interventions reported here are those undertaken in 
saphenous vein grafts.
42
 Finally, our analysis is observational, with inherent limitations of 
any such data analysis. Nonetheless, we used robust statistical analyses including multiple 
logistic regression and propensity-matching to adjust for known confounders. 
Conclusion 
In one of the largest analyses to date, we have observed that patients receiving DES 
(particularly newer generation DES) for the treatment of SVG disease have lower rates of in-
hospital MACE, 30-day mortality and 1-year mortality, compared with those receiving BMS. 
Patients undergoing PCI for SVG disease should therefore receive a DES, unless any 
contraindication or higher risk of bleeding with DAPT or requirement for a short DAPT 
course.  
Acknowledgement  
The authors acknowledge the North Staffs Heart Committee for providing financial support 
for this study. 
Funding 
The North Staffs Heart Committee. 
Disclosures 
None. 
 
References 
 
1. Borges JC, Lopes N, Soares PR, Gois AF, Stolf NA, Oliveria SA, Hueb WA, Ramires 
JA. Five-year follow-up of angiographic disease progression after medicine, 
angioplasty, or surgery. J Cardiothor Surg 2010;5:91. 
2. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary 
bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related 
to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 
1996;28:616-26. 
3. Bourassa MG, Fisher LD, Campeau L, Gillespie MJ, McConney M, Lesperance J. 
Long-term fate of bypass grafts: the Coronary Artery Surgery Study (CASS) and 
Montreal Heart Institute experiences. Circulation 1985;72:V71-8. 
4. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read 
R, Chesler E, Sako Y. Saphenous vein graft patency 1 year after coronary artery 
bypass surgery and effects of antiplatelet therapy. Results of a Veterans 
Administration Cooperative Study. Circulation 1989;80:1190-7. 
5. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K ,Ovitt T, Kern KB, Sethi 
G, Sharma GV, Kuri S. Long-term graft patency (3 years) after coronary artery 
surgery. Effects of aspirin: results of a VA Cooperative study. Circulation 
1994;89:1138-43. 
6. Campbell PG, Teo KS, Worthley SG, Kearney MT, Tarique A, Natarajan A, Zaman 
AG. Non-invasive assessment of saphenous vein graft patency in asymptomatic 
patients. Br J Radiol 2009;82:291-5. 
7. Widimsky P, Straka Z, Stros P, Jirasek K, Dvorak J, Votava J, Lisa L, Budesinsky T, 
Kolesar M, Vanek T, Brucek P. One-year coronary bypass graft patency: a 
randomized comparison between off-pump and on-pump surgery angiographic results 
of the PRAGUE-4 trial. Circulation 2004;110:3418-23. 
8. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, 
Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT. Efficacy 
and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein 
graft failure following coronary artery bypass graft surgery: PREVENT IV: a 
randomized controlled trial. JAMA 2005;294:2446-54. 
9. Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, Lucke JC, 
Baltz JH, Novitzky D. On-pump versus off-pump coronary-artery bypass surgery. 
New Engl J Med 2009;361:1827-37. 
10. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, 
Krasnicka B, Ellis N, Anderson RJ, Henderson W. Long-term patency of saphenous 
vein and left internal mammary artery grafts after coronary artery bypass surgery: 
results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 
2004;44:2149-56. 
11. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, Esposito R. 
Percutaneous coronary intervention versus repeat bypass surgery for patients with 
medically refractory myocardial ischemia: AWESOME randomized trial and registry 
experience with post-CABG patients. J Am Coll Cardiol 2002;40:1951-4. 
12. Loop FD. A 20-year experience in coronary artery reoperation. Eur Heart J 1989;10 
Suppl H:78-84. 
13. Brilakis ES, Wang TY, Rao SV, Banerjee S, Goldman S, Shunk K, Kar B, Holmes 
DR Jr, Dai D, Chin CT, Harding TM, Roe MT. Frequency and predictors of drug-
eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: 
a report from the American College of Cardiology National Cardiovascular Data 
CathPCI registry. JACC Cardiovasc Interv 2010;3:1068-73. 
14. Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status 
and future directions. Br Med Bull 2013;106:193-211. 
15. Brunner-La Rocca HP, Kaiser C, Pfisterer M. Targeted stent use in clinical practice 
based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur 
Heart J 2007;28:719-25. 
16. Aggarwal V, Stanislawski MA, Maddox TM, Nallamothu BK, Grunwald G, Adams 
JC, Ho PM, Rao SV, Casserly IP, Rumsfeld JS, Brilakis ES, Tsai TT. Safety and 
effectiveness of drug-eluting versus bare-metal stents in saphenous vein bypass graft 
percutaneous coronary interventions: insights from the Veterans Affairs CART 
program. J Am Coll Cardiol 2014;64:1825-36. 
17. Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, Bradshaw A, Metzger C, 
Hermiller J, Krainin F, Juk S, Cheek B, Duff P, SImonton CA. Outcomes with drug-
eluting versus bare-metal stents in saphenous vein graft intervention results from the 
STENT (strategic transcatheter evaluation of new therapies) group. JACC Cardiovasc 
Interv 2009;2:1105-12. 
18. Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, 
Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, 
Richardt G, Schomig A, Kastrai A. Drug-eluting versus bare-metal stents in 
saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. 
Lancet 2011;378:1071-8. 
19. Vermeersch P, Agostoni P, Verheye S, van den Heuvel P, Convens C, Bruining N, 
van den Branden F, van Langenhove G. Randomized double-blind comparison of 
sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous 
vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up 
of the RRISC Trial. J Am Coll Cardiol 2006;48:2423-31. 
20. Vermeersch P, Agostoni P, Verheye S, van den Heuvel P, Convens C, van den 
Branden F, van Langenhove G. Increased late mortality after sirolimus-eluting stents 
versus bare-metal stents in diseased saphenous vein grafts: results from the 
randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007;50:261-7. 
21. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, 
Bissett JK, Sachdeva R, Voudris W, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger 
P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a 
similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of 
Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009;53:919-28. 
22. Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, 
Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, 
Karfofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. Continued benefit 
from paclitaxel-eluting compared with bare-metal stent implantation in saphenous 
vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein 
Grafts) trial. JACC Cardiovasc Interv 2011;4:176-82. 
23. Iqbal J, Kwok CS, Kontopantelis E, de Belder MA, Ludman PF, Giannoudi M, 
Gunning M, Zaman A, Mamas MA. Outcomes following primary percutaneous 
coronary intervention in patients with previous coronary artery bypass surgery. Circ 
Cardiovasc Interv 2016;9:e003151. 
24. Mamas MA, Nolan J, de Belder MA, Zaman A, Kinnaird T, Curzen N, Kwok CS, 
Buchan I, Ludman P, Kontopantelis E. Changes in arterial access site and association 
with mortality in the United Kingdom: Observations from a national percutaneous 
coronary intervention database. Circulation 2016;133:1655-67. 
25. Ratib K, Mamas MA, Anderson SG, Bhatia G, Routledge H, de Belder M, Ludman 
PF, Fraser D, Nolan J. Access site practice and procedural outcomes in relation to 
clinical presentation in 439,947 patients undergoing percutaneous coronary 
intervention in the United kingdom. JACC Cardiovasc Interv 2015;8:20-9. 
26. Mamas MA, Anderson SG, Carr M, Ratib K, Buchan I, Sirker A, Fraser DG, Hildick-
Smith, de Belder M, Ludman PF, Nolan J. Baseline bleeding risk and arterial access 
site practice in relation to procedural outcomes after percutaneous coronary 
intervention. J Am Coll Cardiol 2014;64:1554-64. 
27. Sirker A, Mamas M, Robinson D, Anderson SG, Kinnaird T, Stables R, de Belder 
MA, Ludman P, Hildick-Smith D. Bivalirudin, glycoprotein inhibitor, and heparin use 
and association with outcomes of primary percutaneous coronary intervention in the 
United Kingdom. Eur Heart J 2016;37:1312-20. 
28. Lee MS, Yang T, Kandzari DE, Tobis JM, Liao H, Mahmud E. Comparison by meta-
analysis of drug-eluting stents and bare metal stents for saphenous vein graft 
intervention. Am J Cardiol 2010;105:1076-82. 
29. Meier P, Brilakis ES, Corti R, Knapp G, Shishehbor MH, Gurm HS. Drug-eluting 
versus bare-metal stent for treatment of saphenous vein grafts: a meta-analysis. PLoS 
One 2010;5:e11040. 
30. Joyal D, Filion KB, Eisenberg MJ. Effectiveness and safety of drug-eluting stents in 
vein grafts: a meta-analysis. Am Heart J 2010;159:159-169.e4. 
31. Sanchez-Recalde A, Jimenez Valero S, Moreno R, Barreales L, Lozano I, Galeote G, 
Martin Reyes R, Calvo L, Lopez-Sendon JL. Safety and efficacy of drug-eluting 
stents versus bare-metal stents in saphenous vein grafts lesions: a meta-analysis. 
EuroIntervention. 2010;6:149-60. 
32. Testa L, Agostoni P, Vermeersch P, Biondi-Zoccai G, van Gaal W, Bhindi R, Brilakis 
E, Latini RA, Laudisa ML, Pizzocri S, Lanotte S, Brambilla N, Banning A, Bedogni 
F. Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft 
disease: a systematic review and meta-analysis. EuroIntervention 2010;6:527-36. 
33. Paradis JM, Belisle P, Joseph L, Bertrand OF, DeLarochelliere R, Dery JP, Larose E, 
Rodes-Cabau J, Rinfret S. Drug-eluting or bare metal stents for the treatment of 
saphenous vein graft disease: a Bayesian meta-analysis. Circ Cardiovac Interv 
2010;3:565-76. 
34. Hakeem A, Helmy T, Munsif S, Bhatti S, Mazraeshahi R, Cilingiroglu M, Effat M, 
Leesar M, Arif I. Safety and efficacy of drug eluting stents compared with bare metal 
stents for saphenous vein graft interventions: a comprehensive meta-analysis of 
randomized trials and observational studies comprising 7,994 patients. Catheter 
Cardiovasc Interv 2011;77:343-55. 
35. Mamas MA, Foley J, Nair S, Wiper A, Clarke B, El-Omar M, Fraser DG, Khattar R, 
Neyses L, Fath-Ordoubadi F. A comparison of drug-eluting stents versus bare metal 
stents in saphenous vein graft PCI outcomes: a meta-analysis. J Interv Cardiol 
2011;24:172-180. 
36. Brennan JM, Sketch MH, Jr, Dai D, Trilesskaya M, Al-Heijily W, Brilakis E, 
Messenger JC, Shaw RE, Anstrom KJ, Peterson ED, Douglas PS. Safety and clinical 
effectiveness of drug-eluting stents for saphenous vein graft intervention in older 
individuals: Results from the medicare-linked National Cardiovascular Data Registry 
CathPCI Registry (2005-2009). Catheter Cardiovasc Interv 2016;87:43-9. 
37. Pang S, Shi SY, Zhang YJ, Iqbal J, Chen XY, Ren XM, Zhu H, Zeng YP, Bioh G, 
Bourantas CV, Xu B, Serruys PW, Chen SL. The impact of dual antiplatelet therapy 
duration on primary composite endpoint after drug-eluting stent implantation: A meta-
analysis of 10 randomized trials. Int J Cardiol 2016;202:504-6. 
38. Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, 
Vlachojannis GJ, Jensen LO, Christiansen EH, Berencsi K, Valgimigli M, Orlandi C, 
Petrou M, Rapezzi C, Stone GW. Long-term safety of drug-eluting and bare-metal 
stents evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 
2015;65:2496-2507. 
39. Lee MS, Hu PP, Aragon J, Shah AP, Oyama J, Dhoot J, Iqbal Z, Jones N, Penny W, 
Tobis J, Mahmud E, French W. Comparison of sirolimus-eluting stents with 
paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter 
Southern California Registry). Am J Cardiol 2010;106:337-41. 
40. Papayannis AC, Michael TT, Yangirova D, Abdel-Karim AR, Kohlhaas J, Mahmood 
A, Addo T, Haagen D, Makke L, Roesle M, Rangan B, Banerjee S, Brilakis ES. 
Optical coherence tomography analysis of the stenting of saphenous vein graft (SOS) 
Xience V Study: use of the everolimus-eluting stent in saphenous vein graft lesions. J 
Invasive Cardiol 2012;24:390-4. 
41. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J, Richardt 
G, Iniquez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui 
M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC. 
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. New 
Engl J Med 2015;373:2038-47. 
42. Brilakis ES, Rao SV, Banerjee S, Goldman S, Shunk KA, Holmes DR Jr, Honeycutt 
E, Roe MT. Percutaneous coronary intervention in native arteries versus bypass grafts 
in prior coronary artery bypass grafting patients: a report from the National 
Cardiovascular Data Registry. JACC Cardiovasc Interv 2011;4:844-50. 
Table 1: Descriptive statistics 
Variable Bare metal stent 
(BMS) 
1st gen. DES 2nd gen. DES p-value 
 n=5,685 n=2,265 n=7,053 1st gen. DES 
vs BMS 
2nd gen. DES 
vs BMS 
2nd vs 1st 
gen. DES 
Age 70 (±10)  68 (±9)  69 (±10) <0.001 <0.001 <0.001 
Male gender 4,757 (84%) 1,868 (83%) 5,891 (84%) 0.22 0.98 0.21 
Smoking status 
Never 
Ex-smoker 
Smoker 
 
1,629 (33%) 
2,643 (54%) 
651 (13%) 
 
632 (34%) 
1,013 (55%) 
204 (11%) 
 
2,332 (37%) 
3,230 (52%) 
705 (11%) 
0.053 <0.001 0.038 
Diabetes 1,565 (29%) 645 (31%) 2,236 (33%) 0.096 <0.001 0.050 
Hypertension 3,539 (64%) 1,351 (63%) 4,674 (68%) 0.54 <0.001 <0.001 
Hyperlipidemia 3,564 (65%) 1,440 (67%) 4,740 (69%) 0.014 <0.001 0.22 
Previous MI 3,250 (61%) 1,231 (60%) 4,071 (61%) 0.23 0.66 0.36 
Previous stroke 373 (7%) 111 (5%) 467 (7%) 0.012 0.94 0.009 
Peripheral vascular 
disease 
592 (11%) 198 (9%) 680 (10%) 0.064 0.13 0.41 
Renal disease 267 (5%) 90 (4%) 317 (5%) 0.24 0.57 0.43 
Previous PCI 1,836 (34%) 903 (43%) 2,862 (42%) <0.001 <0.001 0.21 
Left ventricular ejection 
fraction 
Good 
Moderate  
Poor 
 
 
1,497 (53%) 
1,004 (35%) 
342 (12%) 
 
 
640 (57%) 
355 (32%) 
123 (11%) 
 
 
2,097 (57%) 
1,288 (35%) 
316 (9%) 
0.033 <0.001 0.017 
Family history of CAD 2,404 (52%) 994 (55%) 2,967 (49%) 0.019 0.004 <0.001 
Radial access 1,402 (25%) 373 (17%) 2,435 (35%) <0.001 <0.001 <0.001 
Glycoprotein IIb/IIIa 
inhibitor 
1,374 (25%) 675 (32%) 1,351 (20%) <0.001 <0.001 <0.001 
Bivalirudin 95 (2%) 30 (2%) 167 (2%) 0.37 0.013 0.010 
Multivessel disease 820 (14%) 604 (27%) 1,511 (21%) <0.001 <0.001 <0.001 
Cardiogenic shock 125 (2%) 9 (0.5%) 73 (1%) <0.001 <0.001 0.010 
Intra-aortic balloon 
pump 
134 (2%) 30 (1%) 77 (1%) 0.008 <0.001 0.26 
Thrombus aspiration 481 (9%) 68 (3%) 603 (9%) <0.001 0.83 <0.001 
Ventilatory support 83 (2%) 10 (0.6%) 61 (1%) 0.001 0.001 0.098 
Embolic protection 
device 
875 (16%) 311 (14%) 1,021 (15%) 0.13 0.19 0.56 
Diagnosis 
Stable angina 
NSTEMI 
STEMI 
 
2,082 (38%) 
2,682 (49%) 
693 (13%) 
 
1,122 (51%) 
980 (45%) 
88 (4%) 
 
2,689 (39%) 
3,521 (51%) 
686 (10% 
<0.001 <0.001 <0.001 
In-hospital MACE 167 (3%) 31 (1%) 103 (2%) <0.001 <0.001 0.87 
Death at 30 days 171 (3%) 21 (0.9%) 94 (1%) <0.001 <0.001 0.13 
Death at 365 days 491 (9%) 106 (5%) 371 (6%) <0.001 <0.001 0.058 
BMS=bare metal stent, DES=drug eluting stent, gen.=generation, MI=myocardial infarction, PCI=percutaneous coronary intervention, 
CAD=coronary artery disease, NSTEMI=non-ST-elevated myocardial infarction, STEMI=ST-elevation myocardial infarction, MACE=major 
adverse cardiovascular events. 
Table 2: Multivariable logistic regression for adverse outcomes according to stent type with multiple imputations 
 
Outcomes* Odds ratio (95% CI) p-value 
In-hospital MACE (n=15,003) 
Bare metal stent 
1st generation DES 
2nd generation DES 
 
1.00 (reference) 
0.77 (0.50-1.21) 
0.51 (0.38-0.68) 
 
 
0.262 
<0.001 
Mortality at 30 days (n=15,003) 
Bare metal stent 
1st generation DES 
2nd generation DES 
 
1.00 (reference) 
0.63 (0.37-1.10) 
0.43 (0.32-0.59) 
 
 
0.104 
<0.001 
Mortality at 365 days (n=15,003) 
Bare metal stent 
1st generation DES 
2nd generation DES 
 
1.00 (reference) 
0.78 (0.61-1.01) 
0.60 (0.51-0.71) 
 
 
0.059 
<0.001 
MACE=major adverse cardiovascular events, DES=drug eluting stent 
Multivariable estimates with 10 imputations and adjusted for age, sex, smoking status, diabetes, hypertension, hyperlipidemia, previous 
myocardial infarction, previous stroke, peripheral vascular disease, renal disease, previous percutaneous coronary intervention, left ventricular 
ejection fraction, family history of coronary artery, radial access, glycoprotein IIb/IIIa inhibitor, bivalirudin, multivessel disease, cardiogenic 
shock, intra-aortic balloon pump, thrombus aspiration, ventilatory support, embolic protection device and diagnosis. 
Table 3:  Propensity score matching analysis on 10 imputed datasets, reporting average treatment effects (ATE).* 
Analysis Method Group Coefficient† 95% CI p-value 
In-hospital 
MACE 
Propensity 
score 
matching, 
ATE 
1
st
 gen. DES 
vs BMS 
(n=7,950) 
-0.0129 -0.0212 -0.0047 0.002 
2
nd
 gen. DES 
vs BMS 
(n=12,738) 
-0.0096 -0.0165 -0.0028 0.006 
30 day 
mortality 
Propensity 
score 
matching, 
ATE 
1
st
 gen. DES 
vs BMS 
(n=7,950) 
-0.0166 -0.0233 -0.0099 <0.001 
2
nd
 gen. DES 
vs BMS 
(n=12,738) 
-0.0146 -0.0218 -0.0074 <0.001 
1 year 
mortality 
Propensity 
score 
matching, 
ATE 
1
st
 gen. DES 
vs BMS 
(n=7,950) 
-0.0198 -0.0639 0.0244 0.373 
2
nd
 gen. DES 
vs BMS 
(n=12,738) 
-0.0332 -0.0457 -0.0207 <0.001 
MACE=major adverse cardiovascular event, DES=drug eluting stent, BMS=bare metal stent, gen.=generation, ATE=average treatment effect. 
*To better control for the baseline differences across the groups, multiple imputation propensity score matching (mi estimate:teffects psmatch on 
Stata) was used to estimate the average treatment effect (ATE). The method used all the predictors in Table 1 in three separate multiple 
imputation logistic regression models (1st generation DES vs BMS, 2nd generation DES vs BMS and 2nd generation DES vs 1st generation 
DES), calculating propensity scores for group membership. Standard settings for the matching algorithm were used. A minimum of one 
neighbour was requested and all observations were considered as potential matches regardless of how dissimilar their propensity scores were. 
Tolerance for the overlap assumptions was set to 10
-5
. Simple logistic regression models were run (the only predictor being group membership) 
to obtain the ATE and the ATE is a measure of the difference in mean outcomes between participants assigned to the treatment and participants 
assigned to the control.  The output of the teffects psmatch on Stata are coefficients and 95% confidence intervals rather than odds ratios. 
† The coefficient is the difference in probability. Using the first row as an example, a coefficient of -0.0129 means that 1st generation DES are 
1.29% less likely to be associated with in-hospital MACE than BMS.
Figure 1. Flow diagram of participant inclusion. PCI indicates percutaneous coronary 
intervention. 
 
Figure 2. Changes in use of stents over time. BMS indicates bare metal stents; DES, drug-
eluting stent; and PCI, percutaneous coronary intervention. 
 
SUPPLEMENTARY MATERIAL 
 
Supplemental Table 1: Missing data 
Variable Number of available 
values (%) 
Number of missing 
values (%) 
Age 14,998 (99.97%) 5 (0.03%) 
Male gender 14,969 (99.8%) 34 (0.2%) 
Smoker (current or ex) 13,039 (87%) 1,964 (13%) 
Diabetes 14,383 (96%) 620 (4%) 
Hypertension 14,539 (97%) 464 (3%) 
Hyperlipidemia 14,539 (97%) 464 (3%) 
Previous MI 14,041 (94%) 962 (6%) 
Previous stroke 14,539 (97%) 464 (3%) 
Peripheral vascular 
disease 
14,539 (97%) 464 (3%) 
Renal disease 14,785 (99%) 218 (1%) 
Previous PCI 14,433 (96%) 570 (4%) 
Left ventricular 
ejection fraction 
7,662 (51%) 7,341 (49%) 
Family history of CAD 12,515 (83%) 2,488 (17%) 
Radial access 14,644 (98%) 359 (2%) 
Glycoprotein IIb/IIIa 
inhibitor 
14,107 (94%) 896 (6%) 
Bivalirudin use 13,999 (93%) 1,004 (7%) 
Multivessel disease 12,068 (80%) 2,935 (20%) 
Cardiogenic shock 13,589 (91%) 1,414 (9%) 
Use of intra-aortic 
balloon pump 
14,309 (95%) 694 (5%) 
Thrombus aspiration 14,414 (96%) 589 (4%) 
Ventilatory support 13,288 (89%) 1,715 (11%) 
Embolic protection 
device 
14,502 (97%) 501 (3%) 
Diagnosis 14,543 (97%) 460 (3%) 
Year 15,003 (100%) 0 (0%) 
MACE 14,470 (96%) 533 (4%) 
Death at 30 days 15,003 (100%) 0 (0%) 
Death at 365 days 14,268 (95%) 735 (5%) 
MI=myocardial infarction, PCI=percutaneous coronary intervention, MACE=major adverse 
cardiovascular event. 
Supplemental Table 2: Outcomes which collectively combine to produce in-hospital MACE 
Variable Bare metal 
stent 
(BMS) 
1st gen. 
DES 
2nd gen. 
DES 
p-value 
6,680 2,101 5,987 1st gen. 
DES vs 
BMS 
2nd gen. 
DES vs 
BMS 
2nd vs 1st 
gen. DES 
Non-q wave 
myocardial 
infarction 
31 (0.46%) 11 
(0.52%) 
23 
(0.38%) 
0.73 0.49 0.40 
Death in-
hospital 
100 (1.5%) 13 
(0.62%) 
52 
(0.87%) 
0.002 0.001 0.27 
Reinfarction 7 (0.10%) 2 (0.10%) 6 (0.10%) 0.91 0.94 0.95 
Reintervention 
PCI 
32 (0.48%) 5 (0.24%) 14 
(0.23%) 
0.14 0.022 0.97 
BMS=bare metal stent, DES=drug eluting stent, gen.=generation, PCI=percutaneous 
coronary intervention. 
Supplemental Table 3: Matching success diagnostics for propensity model 
 
Comparison Group Mean (SD) Median (IQR) 
1
st
 generation DES vs 
BMS  
 
Case (1
st
 gen DES) 0.7151 (0.2231) 0.7000 (0.5236-
0.9939) 
Control (BMS) 0.7151 (0.2230) 0.7000 (0.5235-
0.9940) 
Abs(Case-Control) 0.00029 (0.00110) 0.00011 (0.00004-
0.00027) 
2
nd
 generation DES 
vs BMS  
Case (2
nd
 gen DES) 0.4563 (0.2558) 0.3400 (0.2541-
0.6320) 
Control (BMS) 0.4463 (0.2557) 0.3400 (0.2542-
0.6319) 
Abs(Case-Control) 0.00019 (0.00139) 0.00005 (0.00002-
0.00014) 
BMS=bare metal stent, DES=drug eluting stent, gen.=generation, PCI=percutaneous 
coronary intervention, IQR=interquartile range. 
Distribution of propensity scores and residual propensity score differences between pairing 
for each comparison are shown and quality of matching for propensity matched imputed 
cohort. 
Supplemental Table 4:  Propensity score matching analysis on 10 imputed datasets, 
reporting odds ratios (transformed from the average treatment effect reported in Table 3 of 
the main paper) 
Analysis Method Group Odds ratio 95% CI p-value 
In-hospital 
MACE 
Propensity 
score 
matching, 
ATE 
1
st
 gen. DES vs 
BMS 
(n=7,950) 
0.56 0.29 0.84 0.002 
2
nd
 gen. DES 
vs BMS 
(n=12,738) 
0.67 0.44 0.90 0.006 
30 day 
mortality 
Propensity 
score 
matching, 
ATE 
1
st
 gen. DES vs 
BMS 
(n=7,950) 
0.44 0.22 0.66 <0.001 
2
nd
 gen. DES 
vs BMS 
(n=12,738) 
0.51 0.27 0.75 <0.001 
1 year 
mortality 
Propensity 
score 
matching, 
ATE 
1
st
 gen. DES vs 
BMS 
(n=7,950) 
0.76 0.27 1.31 0.373 
2
nd
 gen. DES 
vs BMS 
(n=12,738) 
0.61 0.47 0.75 <0.001 
MACE=major adverse cardiovascular events, BMS=bare metal stent, DES=drug eluting 
stent, gen.=generation, ATE=average treatment effects. 
